Tag: UBS analyst Eliana Merle
-
CureVac is an Underappreciated Opportunity, Says UBS
Investors may want to keep an eye on CureVac (CVAC). After pulling back from about $12.50 to $10.50, CVAC could see higher highs. In fact, according to a UBS analyst, the stock is ready to compete in the big leagues. “UBS analyst Eliana Merle upgraded the shares to Buy from Neutral and raised her 12-month…